IFF outlines a Scent recovery driven by Fragrance Ingredients momentum and a robust R&D build, with Fine Fragrance softening in Q3 and strengthening in Q4, while Consumer Fragrance stabilizes through renewed R&D and go-to-market execution ahead of 2027.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
In Q2, the Scent team reported 8% segment sales growth (to $665 million) with performance driven by double-digit growth in Fragrance Ingredients and a high single-digit increase in Consumer Fragrance; Fine Fragrance grew low single digits, “inclusive of the impact of the Middle East conflict.” 1
The Q2 call commentary attributes part of the Scent recovery momentum to Fragrance Ingredients: it grew north of 20% in Q2, helped by a difficult year-ago comparison (down 10% or more) and also by tactical leverage of the synthetics portfolio to capture sales amid macroeconomic conditions, supply chain disruptions, and higher Brent crude prices. 2
Management expects Fragrance Ingredients to normalize as conditions settle, specifically shifting toward higher value-added ingredients vs. traditional synthetics, with that shift underway but expected to take more time into next year and the year after (not the second half of 2026). 3
Fine Fragrance has faced uncertainty from Middle East-related volatility; management explicitly notes a “noise” effect from the Middle East conflict on Fine Fragrances. 4
However, the team demonstrated resilience in Q2: Fine Fragrance finished up slightly positive versus an expectation heading into the quarter of mid-single-digit declines. 2
Looking forward, management is modeling continued headwinds and recovery timing: for the second half, they expect Fine Fragrance to be softer in Q3 but stronger in Q4, targeting mid-single-digit growth on a second-half basis. 3
This view is reinforced by the magnitude of the comparables: Q3 last year Fine Fragrance grew 20%, so Q3 faces a big tough comp even as the business trends “in the right direction.” 2
On the Consumer Fragrance side, management describes a recovery framework centered on R&D capability rebuild plus a renewed go-to-market approach with customers to drive market share gains. 3
The trajectory for Consumer Fragrance in H2 is framed as normalization after a strong Q2: management says Consumer Fragrance is in the low single-digit range for the business going forward, with Q2 having been high single-digit and expected to normalize. 3
They also highlight that R&D pipeline and capability improvement is already visible: management states that 2.5 years ago the R&D pipeline was “not what it should have been,” and that today they have a strong R&D capability, “leading-edge new Fine Fragrances and Consumer Fragrances,” and a pipeline of molecules and delivery systems. 5
The company ties progress directly to tangible R&D outputs: management reports stronger pipeline quality and capability—great perfumers developing leading-edge products and a much better R&D pipeline—and expresses optimism about future Scent performance, while still noting the team is “not satisfied” and has work remaining. 5
This connects directly to the “recovery” narrative because the plan is not only to ride cyclical normalization (especially in ingredients), but to rebuild the innovation engine that supports both Fine Fragrance and Consumer Fragrance. 35
Although your question focuses on Fine Fragrance and Consumer Fragrance, Scent’s overall recovery is materially influenced by Fragrance Ingredients:
Management states that the company has rebuilt the Scent R&D engine: compared with 2.5 years ago, when the pipeline was falling behind, they now have:
This is the foundation for supporting evolution into 2027 because it reflects a structural capability (pipeline + perfumery + delivery systems), not merely short-term marketing or channel actions. 5
Management’s H2 framework for Consumer Fragrance includes rebuilding R&D capability and the go-to-market approach with customers, explicitly linked to driving market share gains. 3
This matters for 2027 because share gains generally require sustained product innovation and consistent customer-facing execution—both are described as part of the R&D-supported operating plan. 35
While Fragrance Ingredients normalization is expected in 2026, management indicates that the strategy to shift toward higher-value natural products (instead of traditional synthetics) takes more time and is not expected to fully play out in H2 2026; instead, they expect a really strong competitive position as they progress into next year and the year after. 3
This “longer horizon” ingredient transition aligns with the idea that R&D-enabled product development and differentiation will matter increasingly as the input portfolio shifts—supporting the 2027 outlook. 3
In the broader transformation discussion, management emphasizes that R&D reinvestment (including maintaining ~8% to 9% of sales for R&D as referenced on their slide) is “really important” to set the business apart, and frames it as creating a feedback loop: investment → better growth → margin expansion → further reinvestment. 6
While this comment is portfolio-wide (not solely Scent), it provides context for how management intends to fund R&D capability that will support 2027. 6
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF's Scent segment posted an 8% Q2 sales rise led by double-digit growth in Fragrance Ingredients and a resilient Consumer Fragrance line, even as Fine Fragrance faced Middle East volatility. The firm outlines a two-track H2: mid-single-digit growth for Fine Fragrance with a Q3 soft patch and a rebound in Q4, while Consumer Fragrance normalizes after a standout Q2, underpinned by an R&D-driven push into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is advancing on multiple fronts, led by volume-driven growth, a re-energized R&D pipeline, and stable management of regional volatility. In 2H, Fine Fragrance should soften in Q3 and rebound in Q4, while Consumer Fragrance normalizes to a low single-digit pace, with 2027 R&D investments positioned to bolster long-term competitive strength.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Management ties the Scent recovery to a significantly stronger R&D pipeline and execution, with Scent sales up 8% and EBITDA up 5% driven by volume gains and productivity. For 2H, Fine Fragrance is expected to be soft in Q3 but stronger in Q4, while Consumer Fragrance should normalize to low-single-digit growth; the 2027 plan emphasizes sustained R&D investment, perfumer-led innovation, and a shift toward higher-value natural ingredients.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is led by Fragrance Ingredients and volume gains, with Fine Fragrance expected to be softer in Q3 and rebound in Q4. The company emphasizes a rebuilt R&D pipeline and higher-value product shifts to support competitive positioning into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery driven by a strengthened R&D pipeline, improved go-to-market execution, and a strategy to lift market share across Fine and Consumer Fragrance. The company anticipates a softer Q3 but a stronger Q4 for Fine Fragrance and a normalization to low single-digit growth for Consumer Fragrance in H2, supported by an 8-9% of sales R&D investment through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF Scent’s recovery hinges on a rebuilt R&D engine and market-share gains in Consumer Fragrance, with Fine Fragrance stabilizing amid Middle East volatility and Fragrance Ingredients normalization. In H2, Fine Fragrance is expected to soften in Q3 and strengthen in Q4, while Consumer Fragrance normalizes to low single-digit growth; management also emphasizes sustaining R&D investment around 8-9% of sales to support 2027 competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, better market execution for Consumer Fragrance, and disciplined volatility management in Fine Fragrance amid Middle East challenges. Q3 is expected to soften, while Q4 aims for a meaningful recovery; Fragrance Ingredients momentum should normalize toward higher-value inputs. The company frames a stronger R&D pipeline as the cornerstone of the 2027 growth trajectory.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent rebound hinges on stabilizing Fine Fragrance amid Middle East volatility, with Q3 softness and Q4 rebound, while Consumer Fragrance recovery relies on rebuilt R&D go-to-market capabilities and market-share gains. Fragrance Ingredients provide momentum that is expected to normalize in 2H, underpinning a stronger 2027 pipeline and competitive positioning.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Management outlines a disciplined capex path for Remainco, signaling capex around 5–6% of sales and R&D around 8–9% as a post-divestiture growth engine. They stress reinvestment to fuel innovation, margin expansion, and ongoing value creation, while noting near-term headwinds from the stand-alone transition.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
Dafinchi